デジタルセラピューティクスの市場規模、シェア、動向分析レポート：用途別、最終用途別、地域別、セグメント予測、2025年～2030年

デジタルセラピューティクス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のデジタルセラピューティクス市場規模は2030年までに325億米ドルに達し、2025年から2030年にかけて27.77％のCAGRで成長すると推定されています。

市場成長を促進する主な要因は、スマートフォンの普及です。ヘルスケアプロバイダーや患者にとってデジタルヘルス技術が手ごろな価格で入手可能であること、統合ヘルスケアシステムに対する需要の高まり、患者に焦点を当てたケアが市場成長を促進する主な要因です。さらに、世界化の進展や、タバコの使用率の上昇、栄養不足、運動不足、アルコール消費量の増加などの生活習慣の変化は、慢性疾患発症の可能性を高めています。

市場の拡大は、デジタルセラピューティクスの採用増加や、FDAなどの主要規制機関による支援策に大きく影響されています。例えば、米国FDAは2020年4月、精神疾患を患う人々に対するデジタル治療機器の普及を強化するためのガイドラインを提示しました。さらに、ケピオスのデータによると、世界のインターネット・ユーザーの年間成長率は7.6％で、毎日約90万人の新規インターネット・ユーザーが利用していることになります。先進国も開発途上国もスマートフォンやインターネットの利用レベルは高いが、アフリカや南アジアなどの地域は経済的な制約があるため、追いつく必要があります。

慢性疾患の有病率の増加も市場の成長を後押ししています。CDCのNational Center for Chronic Disease Prevention and Health Promotionによると、アメリカの成人の10人に6人が慢性疾患を患っており、成人の10人に4人は2つ以上の慢性疾患を抱えています。例えば、2022年2月、Teladoc Health, Inc.は、ヘルスケアの成果を改善するための慢性疾患管理ソリューション、Chronic Care Completeを発表しました。心血管疾患、がん、糖尿病、慢性腎臓病、慢性肺疾患、アルツハイマー病は、国内における死亡と身体障害の主な原因として特定されています。

デジタルセラピューティクスは、主に業界の主要企業によるカスタマイズされた治療計画や戦略的取り組みにより、様々な健康状態の治療に不可欠な選択肢となっています。こうした取り組みには、合併・買収、規制当局の承認取得、新製品の導入、パートナーシップの確立などが含まれます。さらに、心血管疾患、糖尿病、不安などの慢性疾患の割合が増加していることが、市場の重要なプレーヤーが治療のためのデジタル・ソリューションに投資する原動力となっています。さまざまな企業が不安管理に特化したデジタル治療製品の開発を進めており、これらの製品の多くは研究開発のさまざまな段階にあります。これは市場成長にとって大きな機会となります。例えば、2023年8月、ウェルドックは、糖尿病管理のためのBlueStarデジタルヘルス・ソリューションについて10回目のFDA 510（k）クリアランスを取得したことを明らかにしました。この認可により、BlueStarは接続されたインスリン投与情報をボーラスインスリン投与のためのカスタマイズされた推奨に組み込むことができます。

デジタル治療市場レポートハイライト

• 糖尿病セグメントは2024年に29.75%の最大市場シェアで市場を独占し、予測期間中に最速のCAGRを記録すると予測されます。
• 患者部門は2024年に34.50%の最大市場シェアを占め、予測期間中に最も速い成長率を記録すると予測されます。
• 北米のデジタルセラピューティクス産業は、2024年に40.11％の収益シェアで世界を支配しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 デジタルセラピューティクス市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• デジタルセラピューティクス市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 デジタル治療市場：用途の推定・動向分析

• 市場シェア、2024年および2030年
• セグメントダッシュボード
• 世界のデジタル治療市場展望
• 糖尿病
• 肥満
• 心血管疾患（CVD）
• 呼吸器疾患
• 禁煙
• 中枢神経系（CNS）疾患
• その他

第5章 デジタルセラピューティクス市場：最終用途の推定・動向分析

• 市場シェア、2024年および2030年
• セグメントダッシュボード
• 世界のデジタル治療市場展望
• 患者
• プロバイダー
• 支払者
• 雇用主
• その他

第6章 デジタルセラピューティクス市場：地域推定・動向分析、用途別、最終用途別

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018年から2030年まで：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート
  • その他中東・アフリカ

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• 企業プロファイル
  • OMADA HEALTH, INC.
  • Welldoc, Inc.
  • 2Morrow, Inc
  • Livongo Health, Inc.（Teladoc Health, Inc.）
  • Propeller Health（ResMed）
  • Fitbit LLC
  • Mango Health
  • CANARY HEALTH
  • Noom, Inc.
  • Pear Therapeutics, Inc.
  • Akili Interactive Labs, Inc.
  • HYGIEIA
  • DarioHealth Corp.
  • BigHealth
  • GAIA AG
  • Limbix Health, Inc.

List of Tables

• TABLE 1 List of secondary sources
• TABLE 2 List of abbreviation
• TABLE 3 North America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• TABLE 4 North America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 5 North America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 7 U.S. macro dynamics
• TABLE 8 U.S. digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 9 U.S. digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 10 Canada macro dynamics
• TABLE 11 Canada digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 12 Canada digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 13 Mexico macro dynamics
• TABLE 14 Mexico digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 15 Mexico digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 16 Europe digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• TABLE 17 Europe digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 18 Europe digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 19 UK macro dynamics
• TABLE 20 UK digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 21 UK digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 22 Germany macro dynamics
• TABLE 23 Germany digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 24 Germany digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 25 France macro dynamics
• TABLE 26 France digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 27 France digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 28 Italy macro dynamics
• TABLE 29 Italy digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 30 Italy digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 31 Spain macro dynamics
• TABLE 32 Spain digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 33 Spain digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 34 Denmark macro dynamics
• TABLE 35 Denmark digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 36 Denmark digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 37 Sweden macro dynamics
• TABLE 38 Sweden digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 39 Sweden digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 40 Norway macro dynamics
• TABLE 41 Norway digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 42 Norway digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 43 Asia Pacific digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• TABLE 44 Asia Pacific digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 45 Asia Pacific digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 46 Asia Pacific digital therapeutics market estimates and forecasts, by therapeutic application, 2018 - 2030 (USD Million)
• TABLE 47 Japan macro dynamics
• TABLE 48 Japan digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 49 Japan digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 50 China macro dynamics
• TABLE 51 China digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 52 China digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 53 India macro dynamics
• TABLE 54 India digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 55 India digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 56 Australia Macro dynamics
• TABLE 57 Australia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 58 Australia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 59 Thailand macro dynamics
• TABLE 60 Thailand digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 61 Thailand digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 62 South Korea macro dynamics
• TABLE 63 South Korea digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 64 South Korea digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 65 Latin America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• TABLE 66 Latin America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 67 Latin America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 68 Brazil macro dynamics
• TABLE 69 Brazil digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 70 Brazil digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 71 Argentina macro dynamics
• TABLE 72 Argentina digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 73 Argentina digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 74 MEA digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• TABLE 75 MEA digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 76 MEA digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 77 South Africa macro dynamics
• TABLE 78 South Africa digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 79 South Africa digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 80 Saudi Arabia Macro dynamics
• TABLE 81 Saudi Arabia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 82 Saudi Arabia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 83 UAE Macro dynamics
• TABLE 84 UAE digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 85 UAE digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 86 Kuwait Macro dynamics
• TABLE 87 Kuwait digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 88 Kuwait digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• TABLE 89 Key company heat map analysis/company position analysis

List of Figures

• FIG. 1 Market segmentation
• FIG. 2 Market research process
• FIG. 3 Estimation methodology
• FIG. 4 Data triangulation techniques
• FIG. 5 Primary research pattern
• FIG. 6 Market research approaches
• FIG. 7 Value-chain-based sizing & forecasting
• FIG. 8 QFD modeling for market share assessment
• FIG. 9 Market formulation & validation
• FIG. 10 Commodity flow analysis
• FIG. 11 Digital therapeutics market snapshot, 2024 (USD Million)
• FIG. 12 Segment snapshot
• FIG. 13 Competitive landscape snapshot
• FIG. 14 Parent market outlook
• FIG. 15 Ancillary market outlook
• FIG. 16 Digital Therapeutics market dynamics
• FIG. 17 Digital therapeutics market driver impact
• FIG. 18 Annual cost per person (USD) for key chronic conditions & by no. of co-morbidities
• FIG. 19 Top countries by smartphone users, 2021
• FIG. 20 Digital therapeutics market restraint impact
• FIG. 21 Market participation categorization
• FIG. 22 Market leaders and innovators
• FIG. 23 Company market position analysis
• FIG. 24 Major deals & strategic alliances analysis
• FIG. 25 Digital therapeutics market: Application movement analysis
• FIG. 26 Digital therapeutics Market: Application dashboard
• FIG. 27 Global diabetes market, 2018 - 2030 (USD Million)
• FIG. 28 Global obesity market, 2018- 2030 (USD Million)
• FIG. 29 Global CVD market, 2018- 2030 (USD Million)
• FIG. 30 Global respiratory diseases market, 2018 - 2030 (USD Million)
• FIG. 31 Global smoking cessation market, 2018 - 2030 (USD Million)
• FIG. 32 Global CNS diseases market, 2018- 2030 (USD Million)
• FIG. 33 Global others market, 2018- 2030 (USD Million)
• FIG. 34 Digital therapeutics market: End Use movement analysis
• FIG. 35 Digital therapeutics market: End Use dashboard
• FIG. 36 Global patients market, 2018- 2030 (USD Million)
• FIG. 37 Global providers market, 2018 - 2030 (USD Million)
• FIG. 38 Global payers market, 2018 - 2030 (USD Million)
• FIG. 39 Global employers market, 2018 - 2030 (USD Million)
• FIG. 40 Global other end uses market, 2018- 2030 (USD Million)
• FIG. 41 Regional marketplace: Key takeaways
• FIG. 42 North America: SWOT analysis
• FIG. 43 North America digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 44 U.S. digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 45 Canada digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 45 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 46 Europe: SWOT analysis
• FIG. 47 Europe digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 48 UK digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 49 Germany digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 50 France digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 51 Italy digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 52 Spain digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 53 Sweden digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 54 Norway digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 55 Denmark digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 56 Asia Pacific: SWOT analysis
• FIG. 57 Asia Pacific Digital Therapeutics market, 2018 - 2030 (USD Million)
• FIG. 58 Japan digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 59 China digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 60 India digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 61 Australia digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• FIG. 62 South Korea digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
• FIG. 63 Thailand digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
• FIG. 64 Latin America: SWOT analysis
• FIG. 65 Latin America digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 66 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 67 Brazil digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 68 Argentina digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 69 Middle East and Africa: SWOT analysis
• FIG. 70 Middle East and Africa digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 71 South Africa digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 72 Saudi Arabia digital therapeutics market, 2018 - 2030 (USD Million)
• FIG. 73 UAE digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• FIG. 74 Kuwait digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• FIG. 75 Heat map analysis
• FIG. 76 List of key emerging companies/technology disruptors/innovators

Digital Therapeutics Market Growth & Trends:

The global digital therapeutics market size is estimated to reach USD 32.5 billion by 2030, registering to grow at a CAGR of 27.77% from 2025 to 2030 according to a new report by Grand View Research, Inc. The primary driver for expanding the market growth is the increased use of smartphones. The affordability of digital health technologies for healthcare providers & patients, rising demand for integrated healthcare systems, and care focusing on the patient are key factors fueling the market's growth. Furthermore, the growing globalization and shifts in lifestyle habits, such as higher rates of tobacco use, inadequate nutrition, insufficient physical activity, and rising alcohol consumption, increase the likelihood of chronic disease development.

The market's expansion is significantly influenced by the increasing adoption of digital therapeutics and the supportive initiatives by leading regulatory agencies such as the FDA. For instance, the U.S. FDA provided guidelines in April 2020 to enhance the reach of digital therapeutic devices for people suffering from psychiatric disorders. Furthermore, according to Kepios data, there's a 7.6% annual growth rate in the global internet user base, translating to around 900,000 new internet users daily. While developed and developing nations boast high smartphone and internet usage levels, areas such as Africa and South Asia need to catch up due to their economic limitations.

Increasing prevalence of chronic diseases is also driving the growth of the market. As per the CDC's National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 American adults suffer from a chronic disease, while 4 out of 10 adults have two or more chronic diseases. For instance, in February 2022, Teladoc Health, Inc. launched Chronic Care Complete, a chronic condition management solution to improve healthcare outcomes. Cardiovascular diseases, cancer, diabetes, chronic kidney disease, chronic lung disease, and Alzheimer's have been identified as the leading causes of death and disability in the country.

Digital therapeutics have become an essential option for treating various health conditions, mainly due to customized treatment plans and strategic initiatives by leading companies in the industry. These actions include mergers and acquisitions, clearing regulatory approvals, introducing new products, and establishing partnerships. Moreover, the growing rates of chronic diseases such as cardiovascular disease, diabetes, and anxiety have driven critical players in the market to invest in digital solutions for treatment. Various companies are in the process of developing digital therapeutic products aimed specifically at managing anxiety, with many of these products in different phases of research and development. This presents a significant opportunity for market growth. For instance, In August 2023, Welldoc revealed it had obtained its 10th FDA 510(k) clearance for the BlueStar digital health solution for diabetes management. This clearance allows BlueStar to incorporate connected insulin dosing information into its customized recommendations for bolus insulin dosing.

Digital Therapeutics Market Report Highlights:

• The diabetes segment dominated the market with largest market share of 29.75% in 2024 and is expected to register the fastest CAGR over the forecast period.
• The patient segment held the largest market share of 34.50% in 2024 and is anticipated to register the fastest growth rate over the forecast period, owing to patients' rapid adoption of digital therapeutics.
• North America digital therapeutics industry dominated globally with a revenue share of 40.11% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Application
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Digital Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Digital Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Digital Therapeutics Market: Application Estimates & Trend Analysis

• 4.1. Application Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Digital Therapeutics Market, by Application Outlook
• 4.4. Diabetes
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Obesity
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Cardiovascular Disease (CVD)
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Respiratory Diseases
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.8. Smoking Cessation
  • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.9. Central Nervous System (CNS) Disease
  • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Digital Therapeutics Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Digital Therapeutics Market, by End Use Outlook
• 5.4. Patients
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Providers
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Payers
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.7. Employers
  • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Digital Therapeutics Market: Regional Estimates & Trend Analysis, By Application, By End Use

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Denmark
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Norway
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.9. Rest of Europe
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework/ reimbursement structure
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Rest of Europe market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.7. Rest of Asia Pacific
    • 6.7.7.1. Key country dynamics
    • 6.7.7.2. Regulatory framework/ reimbursement structure
    • 6.7.7.3. Competitive scenario
    • 6.7.7.4. Rest of Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Rest of Latin America
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Rest of Latin America market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.5. Rest of MEA
    • 6.9.5.1. Key country dynamics
    • 6.9.5.2. Regulatory framework/ reimbursement structure
    • 6.9.5.3. Competitive scenario
    • 6.9.5.4. Rest of MEA market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Company Profiles
  • 7.3.1. OMADA HEALTH, INC.
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Welldoc, Inc.
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. 2Morrow, Inc
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Livongo Health, Inc. (Teladoc Health, Inc.)
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Propeller Health (ResMed)
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Fitbit LLC
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Mango Health
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. CANARY HEALTH
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Noom, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Pear Therapeutics, Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Akili Interactive Labs, Inc.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. HYGIEIA
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. DarioHealth Corp.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. BigHealth
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. GAIA AG
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Limbix Health, Inc.
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives